Edwards Lifesciences price target raised to $106 from $105 at Citi

Citi raised the firm’s price target on Edwards Lifesciences to $106 from $105 and keeps a Buy rating on the shares as part of a Q2 earnings preview for the U.S. medical technology space. While Citi anticipates that investors will “continue to lean into quality names that have consistently beat and raised,” with the significant reset in valuations across the group there is “opportunity across the cap stack,” the analyst tells investors in a research note.